ADHD Medication Use Doubled in Five Years. Data Points to a Missing Conversation.
Last updated:
Your child’s pediatrician writes the prescription in twelve minutes. You fill it, they take it, and the school reports fewer disruptions. That feels like progress. New data from Israel’s Ministry of Health says look harder.
Between 2020 and 2025, ADHD medication consumption in Israel rose 98%. Not 9.8%. Ninety-eight percent. Over the same period, amphetamine-based medications surged 675%, climbing from roughly 25% of the ADHD prescription market to 56%, while methylphenidate-based drugs (Ritalin, Concerta) fell from 75% to 33%. Researchers flagged rising non-medical use among young adults alongside the clinical surge. This is not a story about more children getting the help they need. It is a signal that a system reached for its fastest answer and kept reaching harder.
TL;DR
Israel’s ADHD medication use rose 98% from 2020 to 2025; amphetamine-based drugs surged 675% in the same window.
The United States represents less than 5% of the world’s population but accounts for 83% of global ADHD medication volume.
Stimulant medication manages attention symptoms but does not train the working memory, self-regulation, or organizational systems ADHD disrupts.
Organizational skills training achieves effect sizes of 0.54 to 0.83 for adolescents with ADHD; aerobic exercise consistently improves cognitive symptoms.
Parents should ask what skills-building plan accompanies any prescription — not as an alternative, but as the part the system tends to skip.
A new data report from Israel’s Ministry of Health shows ADHD medication consumption nearly doubled in five years, with amphetamine-based prescriptions surging 675%. Here is what the global pattern means for parents and what the evidence says about building real, lasting skills alongside — or before — medication.
Common questions
Does the ADHD medication surge mean my child will be pressured into medication?
Not automatically. But parents who understand the skills-based evidence are better positioned to ask for a combined approach — medication alongside active skills training — or to explore non-pharmacological options first. Knowing the data puts you in the room as a full participant in that decision, not just a signature on a prescription.
Are there proven non-medication options for ADHD?
Yes. Organizational skills training achieves effect sizes of 0.54 to 0.83 for adolescents with ADHD — meaningful, lasting gains in task and time management. Aerobic exercise consistently improves cognitive attention symptoms. Cognitive behavioral therapy and neuroplasticity-based training are also well-researched. These are evidence-backed options, not fringe alternatives.
If my child’s ADHD medication is working, should I stop it?
That decision belongs to your child’s healthcare provider. The right question is not whether to stop — it is whether the treatment plan also includes building the skills the medication is currently managing for your child. A prescription that works for the school day is a start, not a complete plan.
Can a screener tell me whether my child has ADHD?
A screener is a starting point, not a diagnosis. If your child might need formal accommodations such as an IEP or 504 plan, or you suspect a vision, hearing, or medical cause for their struggles, pursue a professional evaluation — that is the route to those supports and the only accurate picture of what is actually going on.
Israel’s Ministry of Health tracked ADHD medication consumption across the country from 2020 through 2025. Total consumption nearly doubled in five years. The composition shifted sharply: methylphenidate-class drugs, historically the first-line choice, now hold only a third of the market. Amphetamine-family drugs, which carry a higher misuse profile, filled the gap and now represent the majority of all ADHD prescriptions in the country.
Israel is not the outlier it might appear. A 2025 narrative review in the Journal of Clinical Medicine mapped ADHD medication consumption across countries and found steady climbs in most nations. The United States, representing less than 5% of the global population, accounts for 83% of global ADHD medication volume. US stimulant prescriptions surged 250% between 2006 and 2016, a period when ADHD prevalence itself changed only minimally. A 2025 analysis in Frontiers in Psychiatry drew an explicit comparison to the opioid crisis trajectory: amphetamine production in 2006 was roughly 7.9 million grams; by 2021 it had tripled.
A national US survey covering 2019 to 2022 found that approximately one in four adults using prescription stimulants reported misuse, and nearly 9% met criteria for prescription stimulant use disorder, with higher misuse rates among those taking amphetamine-based drugs compared to methylphenidate.
Most reporting on ADHD medication surges frames the numbers as a supply-and-demand question — do more children have ADHD, or are prescriptions too easy to obtain? That frame misses the more consequential question: regardless of whether a diagnosis is appropriate, is the treatment plan building anything durable? The research on organizational skills training, aerobic exercise, and behavioral interventions shows meaningful, lasting effect sizes for children who struggle with attention. A system that escalates toward amphetamines before exhausting those options is optimizing for efficiency, not outcomes. The coverage leaves parents without the leverage to ask for both.
A Prescription Manages the Day. It Does Not Train the Brain That Runs It.
Here is what the coverage rarely says plainly: a stimulant medication manages attention during the hours it is active. It does not train the underlying systems that produce attention. When a child takes it and functions better at school, the working memory, self-regulation, and organizational systems that ADHD disrupts remain untrained. The medication is doing the regulating. That is useful for getting through a school day. It is not sufficient for building a brain that regulates itself when the medication is not on board.
Special education’s own research is clear-eyed on this pattern. It describes a “differential boost” — the right support, at the right moment, lifts a struggling learner more than it lifts anyone else. That is a scaffold doing its job. But the same research documents the failure mode: when a support removes the pressure to build the underlying skill, dependence sets in. The question is not “medication: yes or no.” It is “is this treatment also building something that lasts?”
The skills-based evidence is real and growing. A 2017 meta-analysis of organizational skills training for adolescents with ADHD found effect sizes of 0.54 to 0.83 — meaningful, durable gains in task management, time management, and planning. Aerobic exercise interventions consistently show cognitive benefits for children who struggle with attention. Behavioral therapy, neuroplasticity-based training, and cognitive approaches are better studied than most parents know. These are not fringe alternatives. They are evidence-backed options a system optimized for efficiency rarely leads with, because writing a prescription is faster.
Key Takeaways:
1
ADHD medications nearly doubled in five years: Israel’s Ministry of Health documented a 98% surge in consumption 2020-2025, with amphetamine-based drugs up 675% and now representing the majority of all ADHD prescriptions.
2
Stimulant medication manages symptoms; it does not train the underlying skill: Organizational skills training achieves effect sizes of 0.54 to 0.83 for adolescents with ADHD, with lasting gains in executive function — but the system rarely leads with it.
3
The question is not whether to medicate, but what is being built alongside it: Parents who ask for a skills-building plan alongside any prescription steer their child’s treatment toward lasting gains, not just smoother school days.
What to Ask Before Accepting the Next Prescription as the Full Answer
None of this means medication is wrong for your child. For many children with genuine ADHD, the right medication at the right dose changes what is possible in ways that cannot be reached otherwise. The data does not argue against it. It argues for holding the treatment plan to a higher standard.
Ask the prescriber: what is the plan for building the underlying skills alongside this medication? Is there a behavioral or skills-based component? Are we tracking whether the skills themselves are developing, or only whether the school day is running more smoothly?
Ask yourself what your child understands about their own brain. A child who sees their attention system as something being trained — not fixed, not broken — brings a different quality of effort to that work. Brain-imaging studies from Yale and Stanford show that children who struggle with reading and attention develop the same cognitive pathways as typical learners after intensive, appropriate practice. The brain you are worried about today is not the brain your child will have after a year of the right kind of effort. That is not a motivational claim. It is what the neuroplasticity research actually shows.
The 98% surge in Israel, like the 250% US surge a decade ago, reflects a system that found medication efficient. Efficiency and effectiveness are not the same thing.
Your child’s attention is trainable. That is not a hopeful claim — it is what brain-imaging research from Yale and Stanford actually shows: children who struggle with attention develop the same cognitive pathways as typical learners after intensive, appropriate practice. The villain here is not a doctor or a drug. It is a system that runs on efficiency and stops at “the prescription is working.” The question that cuts through that system is: working to do what, exactly? You are the one positioned to demand a higher bar. The Brain Bloom System trains exactly the cognitive micro-skills ADHD most disrupts — working memory, processing speed, self-regulation, and executive function. Start at All Access.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
